Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 7;14(2):292.
doi: 10.3390/cancers14020292.

Intra-Operative Electron Radiation Therapy (IOERT) Anticipated Boost in Breast Cancer Treatment: An Italian Multicenter Experience

Antonella Ciabattoni  1 , Fabiana Gregucci  2 , Karen Llange  3 , Marina Alessandro  4 , Francesca Corazzi  4 , Giovanni B Ivaldi  5 , Paola Zuccoli  5 , Antonio Stefanelli  6 , Agostino Cristaudo  6 , Vincenzo Fusco  7 , Loredana Lapadula  7 , Alba Fiorentino  2 , Daniela Di Cristino  1 , Francesca Salerno  1 , Marco Lioce  8 , Marco Krengli  9 , Cristiana Vidali  10
Affiliations

Intra-Operative Electron Radiation Therapy (IOERT) Anticipated Boost in Breast Cancer Treatment: An Italian Multicenter Experience

Antonella Ciabattoni et al. Cancers (Basel). .

Abstract

In breast cancer, the use of a boost to the tumor bed can improve local control. The aim of this research is to evaluate the safety and efficacy of the boost with intra-operative electron radiotherapy (IOERT) in patients with early-stage breast cancer undergoing conservative surgery and postoperative whole breast irradiation (WBI). The present retrospective multicenter large data were collected between January 2011 and March 2018 in 8 Italian Radiation Oncology Departments. Acute and late toxicity, objective (obj) and subjective (subj) cosmetic outcomes, in-field local control (LC), out-field LC, disease-free survival (DFS) and overall survival (OS) were evaluated. Overall, 797 patients were enrolled. IOERT-boost was performed in all patients during surgery, followed by WBI. Acute toxicity (≥G2) occurred in 179 patients (22.46%); one patient developed surgical wound infection (G3). No patients reported late toxicity ≥ G2. Obj-cosmetic result was excellent in 45%, good in 35%, fair in 20% and poor in 0% of cases. Subj-cosmetic result was excellent in 10%, good in 20%, fair in 69% and poor in 0.3% of cases. Median follow-up was 57 months (range 12-109 months). At 5 years, in-field LC was 99.2% (95% CI: 98-99.7); out-field LC 98.9% (95% CI: 97.4-99.6); DFS 96.2% (95% CI: 94.2-97.6); OS 98.6% (95% CI: 97.2-99.3). In conclusion, IOERT-boost appears to be safe, providing excellent local control for early-stage breast cancer. The safety and long-term efficacy should encourage use of this treatment, with the potential to reduce local recurrence.

Keywords: Intra-Operative Electron Radiation Therapy (IOERT); anticipated IOERT-boost; cosmetic result; early-stage breast cancer; local recurrence; whole breast irradiation (WBI).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan-Meier curves for in-field Local Control (a), out-field Local Control (b), Disease Free Survival (c) and Overall Survival (d). The dashed lines represent 95% confidence interval in each curve. X axis represents the probability of the event and Y axis the variable time to the event.
See this image and copyright information in PMC

References

    1. I Numeri del Cancro in Italia 2021—AIRTUM-AIOM. [(accessed on 1 December 2021)]. Available online: https://www.aiom.it/i-numeri-del-cancro-in-italia/
    1. AIOM Linee Guida: Neoplasie della Mammella. 2020. [(accessed on 1 December 2021)]. Available online: https://www.aiom.it/wp-content/uploads/2020/10/2020_LG_AIOM_NeoplasieMam....
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Darby S., McGale P., Correa C., Taylor C., Arriagada R., Clarke M., Cutter D., Davies C., Ewertz M., et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet. 2011;378:1707–1716. doi: 10.1016/S0140-6736(11)61629-2. - DOI - PMC - PubMed
    1. Whelan T.J., Pignol J.P., Levine M.N., Julian J.A., MacKenzie R., Parpia S., Shelley W., Grimard L., Bowen J., Lukka H., et al. Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer. N. Engl. J. Med. 2010;362:513–520. doi: 10.1056/NEJMoa0906260. - DOI - PubMed
    1. Haviland J.S., Owen J.R., Dewar J.A., Agrawal R.K., Barrett J., Barrett-Lee P.J., Dobbs H.J., Hopwood P., Lawton P.A., Magee B.J., et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomized controlled trials. Lancet Oncol. 2013;14:1086–1094. doi: 10.1016/S1470-2045(13)70386-3. - DOI - PubMed

LinkOut - more resources